65,437 trials
Ductal Breast Carcinoma in Situ · Lobular Breast Carcinoma in Situ · Stage II Breast Cancer
Primary: The Proportion of Patients With RS 11-25 Who Refused the Assigned Treatment — 0.15 proportion of participants
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
Renal Cell Cancer
Primary: Percentage of Participants With Best Overall Tumor Response — 5.3; 21.9; 39.1; 16.6 percentage of participants
Emphysema · Alpha 1-proteinase Inhibitor Deficiency
Primary: Rate of Change of Adjusted Lung Density — -1.632; -1.352; -1.627; -1.256 g/L per year — p== 0.752
Osteopenia · Osteoporosis
Primary: Number of Participants With Adverse Events (AEs) — 2070; 2173; 945; 1014 participants
Colon Cancer · Rectum Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Asthma
Primary: FEV1 Peak (0-3h) Change From Baseline — 0.225; 0.395; 0.389 Litres (L) — p=<0.0001
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 95.5; 96.6 Percentage of Participants — p=<0.001
Relapsing-Remitting Multiple Sclerosis
Primary: Adjusted Annualized Relapse Rate (ARR) — 0.393; 0.216 relapses per person-years — p=< 0.0001
Relapsing-Remitting Multiple Sclerosis
Primary: Percentage of Subjects With Disease Activity Free Status up to Week 48 — 37.2; 35.3 percentage of subjects
Neuromuscular Diseases
Primary: Change From Baseline Vital Capacity at One Year. — 33.33; -7.41 percentage of Change of vital capacity — p=<0.001
Focal Segmental Glomerulosclerosis
Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving Sustained Remission Rate At Week 104 — 85.8; 83.5; 44.4 Percentage of participants — p=< 0.001
Colorectal Cancer Screening
Primary: Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE) — 6.8; 16.7; 14.0; 14.6 percentage of particpants
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants